ALDXのチャート
ALDXの企業情報
| symbol | ALDx |
|---|---|
| 会社名 | Aldeyra Therapeutics Inc （アルデイラ・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アルディラ・セラピューティックス（Aldeyra Therapeutics Inc）はバイオテクノロジー企業である。同社は主に、遊離アルデヒドとして知られている天然に存在する毒性の化学種に関連すると考えられている免疫介在性、炎症性、希少疾病及び他の疾患を治療する製品の開発に集中する。NS2は、シェーグレン・ラーション症候群（SLS）、円板状エリテマトーデス、急性前部ぶどう膜炎及びマイボーム腺機能不全を伴う紅斑性酒さを含む疾患の治療のために、遊離アルデヒドの捕集・処分を可能にされている製品候補である。同社はまた、NS2と異なるアルデヒドトラップを開発している。平成26年4月7日現在、同社は48人のボランティアでの第I相臨床試験におけるNS2を評価した。 アルデイラ・セラピュ―ティクスは、米国のバイオテクノロジ―企業。アルデヒド類など有毒な化学種の発生によるものと考えられる免疫介在疾患、炎症性疾患、奇病およびその他の疾患向けに、新製品の開発を行う。アルデヒドを除去できる製品を開発し、シェ―グレン・ラ―ション症候群の治療薬NS2の製品候補としてのテストを行う。 Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. |
| 本社所在地 | 131 Hartwell Avenue Suite 320 Lexington MA 02421 USA |
| 代表者氏名 | Todd C. Brady トッドC.ブラディ |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 781-761-4904 |
| 設立年月日 | 38200 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2014年 |
| 従業員数 | － |
| url | www.aldeyra.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aldx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -29.67208 |
| 終値（lastsale） | 12.8 |
| 時価総額（marketcap） | 268478976 |
| 時価総額 | 時価総額（百万ドル） 332.67550 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 292.34136 |
| 当期純利益 | 当期純利益（百万ドル） -29.38821 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 68% to $17.4M. Higher net loss reflects Interest Exp-Net of Capitalized Interest increase of 2% to $54K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.72 to -$0.89. |
ALDXのテクニカル分析
ALDXのニュース
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough 2023/03/30 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of the orally administered RASP modulator ADX-629, an investigational new drug, for the treatment of chronic cough. The multicenter, randomized, double-blind, placebo-controlled, two-period Phase 2 crossover trial enrolled 51 patients with refractory or unexplained chronic cough, which is often defined as a cough that persists for more
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa 2023/03/16 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of retinitis pigmentosa, a group of rare genetic eye diseases characterized by retinal cell death and loss of vision, for which there is no U.S. Food and Drug Administration (FDA)-approved treatment. The open-label, single-center Phase 2 cli
Aldeyra Therapeutics, Inc. (ALDX) Q4 2022 Earnings Call Transcript 2023/03/09 15:45:26 Seeking Alpha
Aldeyra Therapeutics, Inc. (NASDAQ:NASDAQ:ALDX) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ETCompany ParticipantsBruce Greenberg - Interim Chief Financial OfficerTodd Brady -…
Aldeyra Therapeutics GAAP EPS of -$1.06 beats by $0.10 (NASDAQ:ALDX) 2023/03/09 12:03:12 Seeking Alpha
Aldeyra Therapeutics press release (ALDX): FY GAAP EPS of -$1.06 beats by $0.10.Cash, Cash Equivalents, and Marketable Securities of $174.3 Million as of December 31, 2022
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights 2023/03/09 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the year ended December 31, 2022. “Now with Priority Review Designation for the treatment of primary vitreoretinal lymphoma, ADX‑2191 joins reproxalap as the second investigational drug candidate at Aldeyra under ND
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough 2023/03/30 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of the orally administered RASP modulator ADX-629, an investigational new drug, for the treatment of chronic cough. The multicenter, randomized, double-blind, placebo-controlled, two-period Phase 2 crossover trial enrolled 51 patients with refractory or unexplained chronic cough, which is often defined as a cough that persists for more
Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa 2023/03/16 11:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the completion of enrollment in the Phase 2 clinical trial of ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of retinitis pigmentosa, a group of rare genetic eye diseases characterized by retinal cell death and loss of vision, for which there is no U.S. Food and Drug Administration (FDA)-approved treatment. The open-label, single-center Phase 2 cli
Aldeyra Therapeutics, Inc. (ALDX) Q4 2022 Earnings Call Transcript 2023/03/09 15:45:26 Seeking Alpha
Aldeyra Therapeutics, Inc. (NASDAQ:NASDAQ:ALDX) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ETCompany ParticipantsBruce Greenberg - Interim Chief Financial OfficerTodd Brady -…
Aldeyra Therapeutics GAAP EPS of -$1.06 beats by $0.10 (NASDAQ:ALDX) 2023/03/09 12:03:12 Seeking Alpha
Aldeyra Therapeutics press release (ALDX): FY GAAP EPS of -$1.06 beats by $0.10.Cash, Cash Equivalents, and Marketable Securities of $174.3 Million as of December 31, 2022
Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights 2023/03/09 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today reported recent corporate highlights and financial results for the year ended December 31, 2022. “Now with Priority Review Designation for the treatment of primary vitreoretinal lymphoma, ADX‑2191 joins reproxalap as the second investigational drug candidate at Aldeyra under ND
Do investors need to be concerned about Aldeyra Therapeutics Inc. (ALDX)? 2022/12/02 14:48:00 US Post News
Aldeyra Therapeutics Inc. (NASDAQ:ALDX) closed Thursday at $6.16 per share, up from $5.60 a day earlier. While Aldeyra Therapeutics Inc. has overperformed by 10.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALDX fell by -16.53%, with highs and lows ranging from $7.99 to $2.36, whereas […]
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA 2022/12/01 13:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration (FDA), the Company plans to submit an NDA as soon as the end of 2022 for marketing approval of the investigational drug candidate ADX-2191 for the treatment of primary vitreoretinal lymphoma. “Pending FDA review, ADX-2191 could be the first FDA-appro
Aldeyra Therapeutics seeks FDA approval of its treatment for dry eye disease symptoms 2022/11/29 14:37:49 Seeking Alpha
Aldeyra Therapeutics (ALDX) on Tuesday said it had submitted a new drug application to the U.S. FDA for its investigational drug reproxalap for the treatment of dry eye disease symptoms
Aldeyra Therapeutics PT Lowered to $23 at Citi 2022/11/22 12:07:15 Investing.com
https://www.investing.com/news/pro/aldeyra-therapeutics-pt-lowered-to-23-at-citi-432SI-2949775
Investing in Aldeyra Therapeutics Inc. (ALDX) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/11/11 12:54:00 US Post News
The share price of Aldeyra Therapeutics Inc. (NASDAQ:ALDX) rose to $5.50 per share on Thursday from $5.18. While Aldeyra Therapeutics Inc. has overperformed by 6.18%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ALDX fell by -39.49%, with highs and lows ranging from $9.35 to $2.36, […]